Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Futura Medical ( (GB:FUM) ) has provided an update.
Futura Medical plc reported significant financial growth for the year ended December 31, 2024, with revenue increasing by 349% to £13.9 million and a profit after tax of £1.3 million. The company successfully launched its lead product, Eroxon®, in over 15 countries, including an initial launch in the US, which triggered a milestone payment. The launches have provided valuable insights for future rollouts, and the company remains focused on expanding its product range and market presence, supported by a strong R&D pipeline and solid financial position.
More about Futura Medical
Futura Medical plc is a consumer healthcare group specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their core strength lies in research, development, and commercialization of topically delivered gel formulations, with their lead product Eroxon® designed for the treatment of erectile dysfunction (ED). The company has distribution partners in major consumer markets, including the US and Europe.
YTD Price Performance: -68.72%
Average Trading Volume: 711,443
Technical Sentiment Signal: Strong Buy
Current Market Cap: £30.08M
See more insights into FUM stock on TipRanks’ Stock Analysis page.